Drug Pricing / Negotiation
Expert articles and analysis related to drug pricing / negotiation.
AI Summary — Last 7 Days
Recent expert discussion on Drug Pricing / Negotiation. See linked articles for details.
Related Articles
Hospitals, insurers clash on 340B rebate costs
Hospitals and insurers both urged federal regulators to ignore the cost projections of the other side in their comments on a coming redux of a 340B rebate model. The comments came in response to a req...
PBMs lean on private label biosimilars to cut costs, boost profit
PBMs lean on private label biosimilars to cut costs, boost profit Modern Healthcare
Humana teams with Mark Cuban's Cost-Plus Drug Company
Humana's CenterWell Pharmacy has teamed with the Mark Cuban Cost Plus Drug Co. on a new employer-based program.Cost Plus Drugs has selected CenterWell Pharmacy as a pharmacy partner. Its digital pharm...
HRSA wants a 340B rebate pilot. Here’s what the industry thinks
HRSA wants a 340B rebate pilot. Here’s what the industry thinks Modern Healthcare
STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch up with drugmakers and patients
AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy
AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy American Hospital Association
340B is a Hidden Tax Expenditure
That is the argument made by Ike Brannon and Anthony Lo Sasso in a recent Health Affairs Forefront article. 340B allows hospitals serving low income communities to purchase pharmaceuticals at discount...
The 340B Drug Pricing Program Is A Hidden Tax Expenditure
The 340B Drug Pricing Program Is A Hidden Tax Expenditure Health Affairs
STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House